Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761324 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2022.06.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report.
J Med Case Rep
December 2024
Emergency Medicine, Vancouver General Hospital, Vancouver, Canada.
Background: Immunotherapy, including the use of immune checkpoint inhibitors such as nivolumab, is increasingly common in cancer treatment and can lead to various immune-related adverse effects, including rare cases of diabetic ketoacidosis. This case report highlights an unique instance of nivolumab-induced diabetic ketoacidosis in a patient without prior history of diabetes, emphasizing the importance of careful monitoring even in those without traditional risk factors.
Case Presentation: We report a case of a 70-year-old Caucasian male with metastatic esophageal adenocarcinoma who developed diabetic ketoacidosis 3 weeks after stopping nivolumab therapy.
Clinical features, treatment, and outcomes of nivolumab induced psoriasis.
Invest New Drugs
December 2024
Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, Hunan, 410013, China.
Psoriasis is an uncommon immune-mediated adverse event linked to nivolumab, and its clinical characteristics remain inadequately defined. This study aims to investigate the clinical features and patterns of nivolumab-induced psoriasis, providing insights for the identification and management of this condition. Case reports and case series of nivolumab related psoriasis were gathered by searching Chinese and English databases for retrospective analysis until June 30, 2024.
View Article and Find Full Text PDFNivolumab - A Double-Edged Sword? A Rare Case of Nivolumab-Induced Myasthenia Gravis and Hepatitis in a Patient with Carcinoma Lung.
Neurol India
November 2024
Department of Medical Oncology, Apollo Hospitals, Bengaluru, Karnataka, India.
Nivolumab-induced hidradenitis suppurativa: a case report.
Dermatol Online J
August 2024
University of Michigan Medical School, Ann Arbor, Michigan, USA.
We present a 44-year-old man with metastatic clear cell renal cell cancer undergoing treatment with nivolumab immunotherapy. Three months post-initiation, he developed symmetric recurrent nodules and boils in intertriginous areas, diagnosed as stage II hidradenitis suppurativa of the groin and gluteal cleft. The progressive course, lesion symmetry and location, worsening with nivolumab infusions, and biopsy findings supported the diagnosis.
View Article and Find Full Text PDFNivolumab-Induced Immune Mediated Colitis Localized to the Distal Colon: Seven Years Into Therapy.
Cureus
October 2024
Pathology, Heartland Pathology Laboratories, Wichita, USA.
Nivolumab targets programmed cell death protein 1 (PD-1) and is used in cancer treatment by increasing the immune response. It has rarely been associated with immune-mediated colitis (IMC). We present a 66-year-old man with metastatic lung adenocarcinoma, treated with nivolumab for seven years, who developed tenesmus and mucoid bloody diarrhea.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!